128 related articles for article (PubMed ID: 34874277)
41. Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.
Lennon P; Deady S; White N; Lambert D; Healy ML; Green A; Kinsella J; Timon C; O' Neill JP
Ir J Med Sci; 2017 Feb; 186(1):89-95. PubMed ID: 27083464
[TBL] [Abstract][Full Text] [Related]
42. Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway.
Burdine LJ; Burdine MS; Moreland L; Fogel B; Orr LM; James J; Turnage RH; Tackett AJ
PLoS One; 2015; 10(6):e0127943. PubMed ID: 26065416
[TBL] [Abstract][Full Text] [Related]
43. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
44. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
[TBL] [Abstract][Full Text] [Related]
45. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
Yeganeh MZ; Sheikholeslami S; Hedayati M
Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
[TBL] [Abstract][Full Text] [Related]
46. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
47. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
[TBL] [Abstract][Full Text] [Related]
48. Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line.
Nozhat Z; Zarkesh M; Baldini E; Mohammadi-Yeganeh S; Azizi F; Hedayati M
Anticancer Agents Med Chem; 2022; 22(4):713-720. PubMed ID: 33461474
[TBL] [Abstract][Full Text] [Related]
49. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
50. Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.
Ciampi R; Romei C; Cosci B; Vivaldi A; Bottici V; Renzini G; Ugolini C; Tacito A; Basolo F; Pinchera A; Elisei R
Mol Cell Endocrinol; 2012 Jan; 348(1):176-82. PubMed ID: 21867742
[TBL] [Abstract][Full Text] [Related]
51. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
52. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
53. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
[TBL] [Abstract][Full Text] [Related]
54. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
[TBL] [Abstract][Full Text] [Related]
55. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.
Ceolin L; Siqueira DR; Ferreira CV; Romitti M; Maia SC; Leiria L; Crispim D; Ashton-Prolla P; Maia AL
Eur J Endocrinol; 2012 May; 166(5):847-54. PubMed ID: 22345297
[TBL] [Abstract][Full Text] [Related]
56. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
57. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
[TBL] [Abstract][Full Text] [Related]
58. A Novel Double
Mathew A; Latteyer S; Frank-Raue K; Moeller LC; Zwanziger D; Mengel M; Führer D; Tiedje V
Thyroid; 2021 Feb; 31(2):327-329. PubMed ID: 32546069
[No Abstract] [Full Text] [Related]
59. Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.
Mishra V; Kowtal P; Rane P; Sarin R
Cancer Med; 2019 Oct; 8(13):6151-6161. PubMed ID: 31408923
[TBL] [Abstract][Full Text] [Related]
60. Variability in Medullary Thyroid Carcinoma in
Mathiesen JS; Nielsen SG; Rasmussen ÅK; Kiss K; Wadt K; Hermann AP; Nielsen MF; Larsen SR; Brusgaard K; Frederiksen AL; Godballe C; Rossing M
Front Endocrinol (Lausanne); 2020; 11():251. PubMed ID: 32411094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
